Table 1.
Patient characteristics
| Minocycline (n=19) | Placebo (n=21) | P value | ||||
|---|---|---|---|---|---|---|
|
Continuous variables, mean (SD), median (range) |
Mean (SD) | Median (min-max) | Mean (SD) | Median (min-max) | ||
| Age, years | 62.4 (8.1) | 63 (47-83) | 67.3 (6.3) | 68 (56-77) | 0.037 | |
| Body mass index | 33.0 (12.6) | 28.3 (17.5-69.3) | 29.2 (7.8) | 28.7 (18.3-48.7) | 0.261 | |
| Total radiation dose, Gy | 62.9 (10.4) | 66 (25-72) | 62.5 (5.4) | 66 (54-74) | 0.229 | |
| Total fractions | 32.7 (4.8) | 33 (25-50) | 32.6 (2.6) | 33 (27-37) | 0.895 | |
| Categorical variables, n, % | ||||||
| Sex | Female | 10 | 52.6% | 10 | 47.6% | 0.752 |
| Male | 9 | 47.4% | 11 | 52.4% | ||
| Marriage | Married | 17 | 89.5% | 15 | 71.4% | 0.154 |
| Unmarried | 2 | 10.5% | 6 | 28.6% | ||
| Race/ethnicity | Non-Hispanic white | 17 | 89.5% | 19 | 90.5% | 0.916 |
| Other | 2 | 10.5% | 2 | 9.5% | ||
| Education | 13 years or more | 10 | 52.6% | 11 | 52.4% | 0.987 |
| 0-12 years | 9 | 47.4% | 10 | 47.6% | ||
| Cancer stage | I/II | 3 | 15.8% | 7 | 33.3% | 0.201 |
| III/IV | 16 | 84.2% | 14 | 66.7% | ||
| Charlson Comorbidity Index | 0 | 10 | 52.6% | 12 | 57.1% | 0.775 |
| 1 or more | 9 | 47.4% | 9 | 42.9% | ||
| ECOG PS | 0 | 11 | 57.9% | 6 | 28.6% | 0.061 |
| 1 | 8 | 42.1% | 15 | 71.4% | ||
| Recurrent disease | No | 18 | 94.7% | 20 | 95.2% | 0.942 |
| Yes | 1 | 5.3% | 1 | 4.8% | ||
| Prior treatment | No | 15 | 78.9% | 13 | 61.9% | 0.240 |
| Yes | 4 | 21.1% | 8 | 38.1% | ||
| Prior radiation | No | 19 | 100.0% | 21 | 100.0% | |
| Yes | 0 | 0.0% | 0 | 0.0% | ||
| Prior chemotherapy | No | 16 | 84.2% | 14 | 66.7% | 0.201 |
| Yes | 3 | 15.8% | 7 | 33.3% | ||
| Prior surgery | No | 17 | 89.5% | 17 | 81.0% | 0.451 |
| Yes | 2 | 10.5% | 4 | 19.0% | ||
| Radiotherapy | 0.115 | |||||
| IMRT | 16 | 84 | 13 | 62 | ||
| Proton | 3 | 16 | 8 | 38 | ||
SD, standard deviation; ECOG PS, Eastern Oncology Group Performance Status